SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is experiencing heightened community interest driven by anticipation of a potential bull cycle and renewed discussion surrounding its correlation with Bitcoin, while traders remain divided between bullish expectations of future price growth and bearish concerns about its long-term viability as a meme asset.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as investors monitor ongoing governance discussions surrounding potential fee switch activation and token burn mechanisms aimed at enhancing protocol revenue and long-term value. Market sentiment remains divided, with some traders viewing the current price levels as an accumulation opportunity for the long-term, while others express caution due to broader crypto market volatility and concerns over structural price action.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Investors are closely monitoring upcoming earnings as they look for confirmation of the company's commercial execution, particularly the growth trajectories of key products like Vevye and Iheezo. Discussion remains centered on evaluating the company's ability to achieve its full-year revenue guidance amid past volatility in management's forecasting and the ongoing impact of strategic shifts in their branded pharmaceutical portfolio.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending primarily due to increased trading volume and volatility following its listing on the Upbit exchange. While some traders view the recent price action as a sustainable breakout driven by new market access, others characterize it as a typical pump-and-dump scheme that will soon retrace.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending as traders speculate on its potential for a major price move, often comparing its privacy-focused utility and supply dynamics to Zcash. While some users are bullish on its long-term potential and recent integration developments, others advise caution, citing concerns over market volatility and the asset's history of significant pullbacks.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is receiving attention as traders debate the project's long-term utility in light of institutional developments, such as new Hedera Council members and tokenized real-world asset growth, versus significant frustration over persistent downward price action and the cancellation of planned ETF filings. While some community members view current levels as an accumulation opportunity for a long-term hold, others express skepticism, citing concerns over past performance and the absence of a near-term price catalyst.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as the community debates its long-term potential, with bulls pointing to technical indicators, low miner reserves, and high network uptime to argue the asset is significantly undervalued. Conversely, many traders express frustration over consistent underperformance relative to other cryptocurrencies, citing poor price action and stagnant ratios as reasons for skepticism.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Attention is centered on the reported Google Cloud validation of Rezolve's proprietary database technology and its integration with Subsquid, which traders view as major infrastructure validation. While many are bullish on the potential for institutional adoption and long-term revenue scaling, some skeptics argue the news primary benefit is to Rezolve rather than the SQD token itself.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

The conversation is fragmented, with investors primarily debating the significance of the upcoming Supreme Court ruling on the Hikma litigation and discussing the potential for a future buyout. Common themes include ongoing frustration over stagnant share price performance, speculation regarding a next-generation formulation, and the company's reliance on established REDUCE-IT data.

Cash Cat

Cash Cat is trending as traders speculate on its potential as a flagship meme coin within the Robinhood ecosystem, with many citing its burn mechanisms and utility as reasons for bullish sentiment. While some market participants view the token as a high-potential asset aiming for significant price appreciation, others express skepticism, dismissing it as a volatile, manipulated asset prone to pump-and-dump cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues 

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.

New Strong Buy Stocks for July 6th

BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.

Bull of the Day: Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

• Reported GAAP EPS of -$0.46 down -221.05% YoY
• Reported revenue of $199.88M up 6.32% YoY
• Collegium Pharmaceutical updated its full-year 2026 guidance, now expecting product revenues between $825 million and $855 million and adjusted EBITDA between $445 million and $470 million for the full year.

Collegium Pharmaceutical experienced a GAAP net loss, declining pain portfolio revenues due to Nucynta and Xtampza performance, and faces ongoing integration and regulatory risks related to its recent business acquisitions.

Collegium Pharmaceutical achieved significant growth in its ADHD portfolio, driven by record JORNAY PM adoption, and successfully completed the strategic acquisition of AZSTARYS to strengthen long-term revenue potential.

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical Inc

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$23.53
Prev Close	$23.70
Open	$23.54
Dividend Yield	0.00%
50-Day Moving Average	$31.85
Beta	0.54
Avg. Volume	871,546.93
PE Ratio	19.06

52-Week High	$50.79
52-Week Low	$23.37
Market Capitalization	$766.03M
EPS (Annual)	$1.73
Price to Book	2.45
Revenue Per Employee	$1.85M

Feed

News

Sentiment

Earnings

Fundamentals

Info

COLL Fundamentals